Skip to search formSkip to main contentSkip to account menu

2-Bromoergocryptine Mesylate

Known as: Bromocriptine Mesylate, 2-Bromoergocryptine Mesylate [Chemical/Ingredient], Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)- 
The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine… 
National Institutes of Health

Related topics

Related topics

22 relations
AcromegalyAmenorrheaBromocriptineBromocriptine 0.8 MG Oral Tablet [Cycloset]

Narrower (2)

CyclosetParlodel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
2004
2004
First reported pediatric case of systemic lupus erythematosus associated with prolactinoma.
There is much interest in the possibility that prolactin influences disease activity in systemic lupus erythematosus (SLE). We… 
2002
2002
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
BACKGROUND The complex pharmacological profile of the antiparkinsonian drug budipine influences neurotransmission beyond the… 
1994
1994
Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin.
A 48-year-old man with visual disturbances and subtle features of acromegaly had elevated serum thyrotropin (thyroid-stimulating… 
1989
1989
Bromocriptine and pleuropulmonary disease.
Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically… 
1987
1987
Prolactin modulates the gonadotropin response to the negative feedback effect of testosterone in immature male rats.
The effects of hyperprolactinemia (hyperPRL) and hypoprolactinemia (hypoPRL) on pituitary gonadotropin secretion and the feedback… 
1986
1986
In vivo evidence for dopaminergic regulation of the canine pituitary intermediate lobe.
In order to examine regulation of pituitary intermediate lobe secretion, plasma immunoreactive (i)ACTH, cortisol, and alpha-MSH… 
1981
1981
Regression of pituitary prolactinoma with bromocriptine administration.
IT HAS been demonstrated that treatment with bromocriptine mesylate can reduce the size of pituitary prolactinomas. 1,2 The… 
1980
1980
Bromocriptine Mesylate (Parlodel) in the Management of Amenorrhea/Galactorrhea Associated with Hyperprolactinemia
The efficacy and safety of bromocriptine mesylate (5 to 7.5 mg per day for up to 24 weeks) were studied in 22 clinical trials… 
1980
1980
Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome.
A 64-year-old woman with active acromegaly of 33 years' duration, severe carpal tunnel syndrome, and subclinical heart disease… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)